Table 1.
Patient baseline characteristics
| Patient characteristics | Pasireotide LAR 80 mg (n=13) | Pasireotide LAR 120 mg (n=16) | All patients (N=29) |
|---|---|---|---|
| Age (years) | |||
| Median (range, min–max) | 58.0 (42–78) | 60.0 (44–76) | 58.0 (42–78) |
| Age category (years), n (%) | |||
| <65 | 10 (76.9) | 10 (62.5) | 20 (69.0) |
| ≥65 | 3 (23.1) | 6 (37.5) | 9 (31.0) |
| Sex, n (%) | |||
| Male | 4 (30.8) | 5 (31.3) | 9 (31.0) |
| Female | 9 (69.2) | 11 (68.8) | 20 (69.0) |
| Race, n (%) | |||
| Caucasian | 11 (84.6) | 13 (81.3) | 24 (82.8) |
| Black | 2 (15.4) | 1 (6.3) | 3 (10.3) |
| Asian | 0 | 1 (6.3) | 1 (3.4) |
| Other | 0 | 1 (6.3) | 1 (3.4) |
| Ethnicity, n (%) | |||
| Mixed ethnicity | 0 | 1 (6.3) | 1 (3.4) |
| Others | 13 (100.0) | 15 (93.8) | 28 (96.6) |
| Body mass index (kg/m2) | |||
| Median (range, min–max) | 27.10 (21.4–40.7) | 25.90 (18.6–45.1) | 26.10 (18.6–45.1) |
| WHO performance status, n (%) | |||
| No restrictions | 6 (46.2) | 8 (50.0) | 14 (48.3) |
| Only light work | 7 (53.8) | 8 (50.0) | 15 (51.7) |
| Histologic grade, n (%) | |||
| Well differentiated | 11 (84.6) | 12 (75.0) | 23 (79.3) |
| Moderately differentiated | 2 (15.4) | 4 (25.0) | 6 (20.7) |
| Primary site of cancer, n (%) | |||
| Lung | 0 | 4 (25.0) | 4 (13.8) |
| Pancreas | 2 (15.4) | 5 (31.3) | 7 (24.1) |
| Small intestine | 6 (46.2) | 7 (43.8) | 13 (44.8) |
| Colon | 1 (7.7) | 0 | 1 (3.4) |
| Rectum | 1 (7.7) | 0 | 1 (3.4) |
| Others | 3 (23.1) | 0 | 3 (10.3) |
| Current extent of disease*, n (%) – metastatic sites | |||
| Liver | 11 (84.6) | 13 (81.3) | 24 (82.8) |
| Lung | 2 (15.4) | 7 (43.8) | 9 (31.0) |
| Peritoneum | 3 (23.1) | 2 (12.5) | 5 (17.2) |
| Omentum | 3 (23.1) | 1 (6.3) | 4 (13.8) |
| Pancreas | 2 (15.4) | 1 (6.3) | 3 (10.3) |
| Small bowel | 2 (15.4) | 1 (6.3) | 3 (10.3) |
| Ascites (malignant) | 1 (7.7) | 2 (12.5) | 3 (10.3) |
| Bone | 1 (7.7) | 2 (12.5) | 3 (10.3) |
| Prior therapies, n (%) | |||
| Any prior therapy | 13 (100.0) | 15 (93.8) | 28 (96.6) |
| Surgery | 13 (100.0) | 15 (93.8) | 28 (96.6) |
| Radiotherapy | 2 (15.4) | 4 (25.0) | 6 (20.7) |
| Prior SSA therapy | 12 (92.3) | 14 (87.5) | 26 (89.7) |
Note:
*
Reported for >10% patients.
Abbreviations: LAR, long-acting release; WHO, World Health Organization; SSA, somatostatin analog.